Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Status:
Completed
Trial end date:
2018-11-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if patiromer treatment in chronic kidney disease
(CKD) subjects receiving spironolactone for the treatment of resistant hypertension will
result in more persistent use of spironolactone through prevention of hyperkalemia and lead
to improved blood pressure control compared with treatment with spironolactone alone
(placebo).